STAT+: Pharmalittle: Biogen considers layoffs amid poor Alzheimer’s drug sales; House Dems plan showdown on drug-pricing vote
Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch. …
Earlier this month, Biogen (BIIB) executives admitted publicly that the launch of its Aduhelm treatment for Alzheimer’s disease was going slower than expected. Privately, the company is facing a situation far bleaker than what it has publicly disclosed, forcing Biogen to consider cost-cutting measures, including layoffs, STAT reports. Just over 100 patients had been infused as of Sept. 11 — a number that is rising slowly but drastically below internal projections and Wall Street expectations that thousands of patients would be using the drug by now.
Continue to STAT+ to read the full story…
